AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
https://european-biotechnology.com/wp-content/uploads/2024/04/RS5822_AdobeStock_128463659-scaled.jpeg14402560Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2024-01-29 15:13:072024-07-08 14:57:59Alvotech Advances in Biosimilar Market with Successful AVT03 Study